- « Previous
- Clinical Pharmacology
- Next »
Meclofenamate
CLINICAL PHARMACOLOGY
Meclofenamate
Pharmacodynamics
Meclofenamate sodium is a nonsteroidal agent which has demonstrated anti-inflammatory, analgesic, and antipyretic activity in laboratory animals. The mode of action, like that of other nonsteroidal anti-inflammatory agents, is not known. Therapeutic action does not result from pituitary-adrenal stimulation. In animal studies, meclofenamate sodium was found to inhibit prostaglandin synthesis and to compete for binding at the prostaglandin receptor site. In vitro meclofenamate sodium was found to be an inhibitor of human leukocyte 5-lipoxygenase activity. These properties may be responsible for the anti-inflammatory action of meclofenamate sodium. There is no evidence that meclofenamate sodium alters the course of the underlying disease.
In several human isotope studies, meclofenamate sodium, at a dosage of 300 mg/day, produced a fecal blood loss of 1 to 2 mL per day, and 2 to 3 mL per day at 400 mg/day. Aspirin, at a dosage of 3.6 g/day, caused a fecal blood loss of 6 mL per day.
In a multiple-dose, one-week study in normal human volunteers, meclofenamate sodium had little or no effect on collagen-induced platelet aggregation, platelet count, or bleeding time. In comparison, aspirin suppressed collagen-induced platelet aggregation and increased bleeding time. The concomitant administration of antacids (aluminum and magnesium hydroxides) does not interfere with absorption of meclofenamate sodium.
Pharmacokinetics
Meclofenamate sodium is rapidly absorbed in man following single and multiple oral doses with peak plasma concentrations occurring in 0.5 to 2 hours. Based on a comparison to a suspension of meclofenamic acid, meclofenamate sodium is completely bioavailable.
The plasma concentrations of meclofenamic acid decline monoexponentially following oral administration. In a study in 10 healthy subjects following a single oral dose the apparent elimination half-life ranged from 0.8 to 5.3 hours. After the administration of meclofenamate sodium for 14 days every 8 hours, the apparent elimination half-life ranged from 0.8 to 2.1 hours with no evidence of accumulation of meclofenamic acid in plasma (see Table).
TABLE: SUMMARY OF MECLOFENAMATE SODIUM PHARMACOKINETIC PARAMETERS
| Mean (Range) | Parameter Values (n= 10) | |
| Meclofenamic Acid 100 mgb | ||
| Cmax µg/mLl | 4.8 (1.8-72) | |
| tmax hr2 | 0.9 (0.5-1.5) | |
| Cmin pg/mL3 | 0.2 (0.5-1.5) | |
| CVF mL/min4 | 206.0 (126-342) | |
| Vd/F liters5 | Brand Name: Meclofenamate
Generic Name: Meclofenamate
Next: Meclofenamate - Patient Information »
« Previous: Meclofenamate - Overdosage & Contraindications Report Problems to the Food and Drug Administration You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088. Bookmark this page:
Women's HealthFind out what women really need. 
WebMD Resources
Health Extras
ENABLEX is a prescription medicine used in adults to treat the following symptoms due to a condition called overactive bladder:
IMPORTANT SAFETY INFORMATIONYou should not take once-daily ENABLEX if you have certain types of stomach problems, glaucoma, or have trouble emptying your bladder. Side effects of ENBLEX include blurred vision, and more commonly dry mouth, constipation, indigestion, and abdominal pain. Use caution when doing certain activities until you know how ENBALEX affects you. MeclofenamateHealth Resources
Drug NewsPopular SearchesRxList HomeDrugs & Medications A-Z List Picture Slideshows Pill Identification Tool Diseases & ConditionsDrug Medical Dictionary Alternative Medicine
About RxListContact RxListTerms & ConditionsPrivacy PolicySponsor PolicySite Map WebMD®MedScape®eMedicineHealth®MedicineNet® Copyright © 2008 by RxList Inc.
 RxList does not provide medical advice, diagnosis or treatment. See additional information. | |
Updated & New